(PPHM) Peregrine Pharmaceuticals Shows Encouraging News

Peregrine Pharmaceuticals (PPHM) recently received encouraging news when the company announced that the US Food and Drug Administration (FDA) has agreed on the design for the phase III registration trial for its oncology candidate, bavituximab. Peregrine Pharma is evaluating bavituximab for the second-line treatment of non-small cell lung cancer (NSCLC). Data from a phase IIb trial in patients treated with bavituximab plus Sanofi’s (SNY) Taxotere (docetaxel) helped determine the phase III trial design. The randomized, double-blind, placebo-controlled phase III trial (n=600) will be conducted across the world among stage IIIB/IV non-squamous NSCLC patients, whose disease progressed after standard front-line treatment, with the primary endpoint being overall survival. The study will compare bavituximab plus Taxotere to Taxotere alone. We note that bavituximab is a key pipeline candidate at Peregrine Pharma. In […]